Oncology Highlights – 30/07/2018

Notizia - Recent Pharma, Healthcare and Biotech Happenings

Asher Bio raises $55M; Roche halts Huntington&#...

Asher Bio raises USD 55 Million in Series A financing Asher Biotherapeutics, a biotechnology company developing exactly targeted immunotherapies for cancer and other diseases, raised USD 55 Million...

Mar 25, 2021

Evotec, Takeda Deal; AZ COVID Vaccine US Trials; Promega’s Recognition; Roche's Tecentriq Results in NSCLC
Evotec, Takeda Deal; AZ COVID Vaccine US Trials; Promega’s Recognition; Roche’s Tecentriq Results in NSCLC

Promega Biotech Ibérica Gains Recognition for COVID-19 Response in Spain Promega Biotech Ibérica has been heralded as the business leader in Spain for its COVID-19 response. The company’s innovative approach to deal with COVID-19 and pandemic has led La Razón, a daily newspaper based in Madrid, to felicitate the...

Find More
pharma-happenings-for-gbt-sanofi-eli-lilly-glooko-solid-biosciences
GBT strikes a deal with Sanofi; Lilly’s IL-23 inhibitor shows promise; Glooko raises $30M; FDA uplifts hold on Solid’s DMD gene therapy

Global Blood Therapeutics strikes a deal with Sanofi for sickle cell disease programs As Global Blood Therapeutics works to bring its sickle cell disease drug, Oxbryta, to younger patients, the company is reinforcing its pipeline with a pair of early-stage programs from Sanofi. In exchange for the global righ...

Find More
Merck, Gilead teams up for HIV treatment; Bright Future for Sanofi/Regeneron’s Libtayo; Roche acquires GenMark; FDA okays Melinta’s Kimyrsa
Merck, Gilead teams up for HIV treatment; Bright Future for Sanofi/Regeneron’s Libtayo; Roche acquires GenMark; FDA okays Melinta’s Kimyrsa

Merck, Gilead  to co-develop combined HIV treatments Merck and Gilead have announced a collaboration to investigate Gilead’s investigational capsid inhibitor, lenacapavir, and Merck’s investigational nucleoside reverse transcriptase translocation inhibitor, islatravir, into a two-drug regimen.  Both...

Find More

More Views & Analysis

pharma-happenings-for-valo-health-ventyx-takeda-maverick-therapeutics
Valo Health receives $110M Series B Cognito’s therapy slows Alzheimer’s disease Ventyx Biosciences raises $114M Takeda expands immuno-oncology portfolio

Valo Health receives USD 110 Million Series B from Koch Valo Health launched in September with USD 100 million and a couple of acquisitions under its belt to transform drug development and cut years off R&D timelines. Now, it is filling with USD 110 million from Koch Disruptive Technologies that will bolster...

Find More

Gilead/Kite's Yescarta; Roche discards Tecentriq for bladder cancer
Overwhelming success of Gilead/Kite’s Yescarta; Ridgeback/ Merck in the COVID-19 game; AnaptysBio’s antibody-drug failure; Roche discards Tecentriq for bladder cancer

Gilead's Kite Receives Expanded Approval for its CAR-T Yescarta's in Follicular Lymphoma  Gilead’s Kite has successfully secured success in launching the first-ever chimeric antigen receptor (CAR) T-cell therapy in the Follicular Lymphoma Market. The US FDA approved the Yescarta for adults with relapsed or ...

Find More

recent-pharma-happenings-for-Pfizer AbbVie Novavax Iktos Pfizer
Novavax targets COVID-19 approval; Iktos collaborates with Pfizer; AbbVie bags option to acquire Mitokinin; Presage inks new pact with Merck

Novavax targets approval for the COVID-19 vaccine in the US Novavax is targeting a second-quarter FDA filing for emergency use of its COVID-19 vaccine. The aim hints the U.S. could join the U.K. on the list of countries to permit the vaccine in the first half of the year. The vaccine’s success in a 15,000-sub...

Find More

Evotec, Chinook's CKD Therapy; Junshi, AZ with Toripalimab in China
Evotec, Chinook Teams Up for CKD Therapy; HitGen & UPPTHERA in Drug Delivery Research; Artiva’s $120 M Coup of NK Cell Therapy; Junshi & AZ with Toripalimab in China

Evotec, Chinook Therapeutics to Advance Chronic Kidney Diseases Therapy Market Evotec and Chinook Therapeutics have collaborated to develop and discover precision medicine therapies for patients with chronic kidney diseases (CKD). The duo plans to jointly identify, characterize and validate novel mechanisms and ...

Find More

recent-pharma-biotech-news-updates-happenings-for-beam-grail-quest-diagnostics
Beam makes USD 120M bet; GRAIL and Quest announce the collaboration; Brain organoids mimic infant’s brains; Improvement in T cells to kill cancer

Beam adds to drug delivery stable with USD 120 Million GuideTx buy Beam Therapeutics has taken over a startup whose technology could proffer the biotech’s genetic medicines to more tissues in the body, widening the potential to approach more diseases. Beam announced that it paid USD 120 million upfront to acq...

Find More

recent-pharma-happenings-for-bluebird-pfizer-guardant-astrazeneca
Bluebird suspends gene therapy trials; Cortexyme tripped up by FDA hold; Guardant Health launches surveillance blood test; Enhertu scores approval

Bluebird suspends gene therapy trials after two sickle cell patients develop cancer Bluebird bio has stopped two clinical trials of its sickle cell disease gene therapy after participants developed acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). During the pause, bluebird will assess whether the ...

Find More

Primary Progressive Aphasia (PPA) is a rare neurological disorder that results from the damages to t.....

Find More

An inflammatory disease of large intestine, Ulcerative Colitis (UC), is approached with therapies th.....

Find More

An autosomal metabolic disorder – Pompe disease results in deterioration of organs and tissues as .....

Find More

End-Stage Renal Disease (ESRD) occurs when chronic kidney disease (CKD) has reached the stage where .....

Find More

Wearable technology has been gaining momentum for the last few years as an effect of the fourth indu.....

Find More

Metachromatic Leukodystrophy (MLD) is a rare hereditary disease characterized by the accumulation of.....

Find More